Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Douglas Arnold

Distinguished James McGill Professor

McGill University

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Immunology Immunology professors in Canada

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (19)

David Rudko

McGill University

CANADA

View details

Sunita Venkateswaran

Western University

CANADA

View details

Nuha Alkhawajah

associate professor, consultant neurologist

king saud university

SAUDI ARABIA

View details

Frederik Barkhof

Prof of Neuroradiology

University College London

UNITED KINGDOM

View details

Gavin Giovannoni

Professor of Neurology

Queen Mary University of London

UNITED KINGDOM

View details

Tanuja Chitnis

Professor of Neurology

Harvard Medical School

UNITED STATES

View details

Till Sprenger

University Hospital of Zurich

SWITZERLAND

View details

Wendy Vargas

Columbia University Irving Medical Center

UNITED STATES

View details

Patrick Vermersch

Professor

Université de Lille

FRANCE

View details

Anne Cross

Professor

Washington University in Saint Louis School of Medicine

UNITED STATES

View details

Olaf Stuve

University of Texas Southwestern Medical Center

UNITED STATES

View details

Lawrence Steinman

Professor

Stanford University

UNITED STATES

View details

Maria Pia Sormani

University of Genova

ITALY

View details

Bruce Cree

Professor of Clinical Neurology

University of California, San Francisco

UNITED STATES

View details

Arman Eshaghi

University College London

UNITED KINGDOM

View details

Sridar Narayanan

Assistant Professor

McGill University

CANADA

View details

Menno Schoonheim

Associate Professor

VU medisch centrum

NETHERLANDS

View details

Ludwig Kappos

Professor

University of Basel

SWITZERLAND

View details

Amit Bar-Or

Professor

University of Pennsylvania

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Douglas Arnold

Research Interests

Explore related searches

Articles (20)

Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis

Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial

Developing Interim Outcome Measures for Multi-Arm Multistage Clinical Trials in Multiple Sclerosis

Periventricular gradients in axonal and myelin microstructure are present in people with multiple sclerosis having low and high disability

Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: The LemKids study

Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial

Tolebrutinib Phase 2b Long-Term Extension Study

Enabling new insights from old scans by repurposing clinical MRI archives for multiple sclerosis research

Presence of slowly expanding lesions in multiple sclerosis predicts progressive demyelination within lesions and normal-appearing tissue over time

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations

Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS

Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis

Choroid Plexus Volume in Pediatric-Onset Multiple Sclerosis

Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease

Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study

Epstein–Barr Virus Strongly Associates With Pediatric Multiple Sclerosis, But Not Myelin Oligodendrocyte Glycoprotein‐Antibody‐Associated Disease

A cross‐sectional study of MRI features and the gut microbiome in pediatric‐onset multiple sclerosis

Collaborators (19)

David Rudko

Sunita Venkateswaran

Nuha Alkhawajah

Frederik Barkhof

Gavin Giovannoni

Tanuja Chitnis

Till Sprenger

Wendy Vargas

Patrick Vermersch

Anne Cross

Olaf Stuve

Lawrence Steinman

Maria Pia Sormani

Bruce Cree

Arman Eshaghi

Sridar Narayanan

Menno Schoonheim

Ludwig Kappos

Amit Bar-Or

Make your next move.